Startseite › Nichtkleinzelliges Lungenkarzinom › South Dakota › Sioux Falls
Klinische Studien zu Nichtkleinzelliges Lungenkarzinom in Sioux Falls, SD
19 Studien zu Nichtkleinzelliges Lungenkarzinom suchen Teilnehmer an Standorten in und um Sioux Falls (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Teilnehmer gesuchtPhase 3
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Avera Medical Group, Sioux Falls
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Teilnehmer gesuchtPhase 2
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Teilnehmer gesuchtPhase 3
- Sanford Cancer Center ( Site 3266), Sioux Falls
- Avera Cancer Institute ( Site 3209), Sioux Falls
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Teilnehmer gesuchtPhase 3
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Teilnehmer gesuchtPhase 3
- Avera Cancer Institute, Sioux Falls
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Teilnehmer gesuchtPhase 3
- Sanford Cancer Center ( Site 0053), Sioux Falls
- Avera Cancer Institute- Research ( Site 0090), Sioux Falls
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Avera Cancer Institute- Research, Sioux Falls
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Teilnehmer gesuchtPhase 3
- Research Site, Sioux Falls
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Research Site, Sioux Falls
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Teilnehmer gesuchtPhase 2/3
- Avera Cancer Institute, Sioux Falls
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Teilnehmer gesuchtBeobachtungsstudie
- Sanford Cancer Center ( Site 0038), Sioux Falls
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Teilnehmer gesuchtPhase 1/2
- Sanford Cancer Center ( Site 0038), Sioux Falls
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Teilnehmer gesuchtPhase 2
- Sanford Cancer Center ( Site 0038), Sioux Falls
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Teilnehmer gesuchtPhase 2
- Sanford Cancer Center, Sioux Falls
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2/3
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Nichtkleinzelliges Lungenkarzinom-Studien in anderen Städten
- Houston, TX145 Studien
- New York City, NY121 Studien
- Arlington, VA104 Studien
- Nashville, TN97 Studien
- Boston, MA90 Studien
- Los Angeles, CA87 Studien
- St. Louis, MO73 Studien
- Chicago, IL61 Studien
- Baltimore, MD60 Studien
- San Antonio, TX59 Studien
- Columbus, OH57 Studien
- Washington, DC55 Studien
Weitere Studien in Sioux Falls
- Brustkrebs18 Studien
- Eierstockkrebs16 Studien
- Lungenkrebs14 Studien
- Krebs (alle Arten)13 Studien
- Endometriumkarzinom11 Studien
- Metastasierender Krebs10 Studien
- Kolorektales Karzinom9 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich9 Studien
- Herzinsuffizienz7 Studien
- Dickdarmkrebs7 Studien
- Triple-negatives Mammakarzinom7 Studien
- Prostatakrebs7 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.